Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Crizotinib targets in glioblastoma stem cells.

Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, Karayan-Tapon L.

Cancer Med. 2017 Nov;6(11):2625-2634. doi: 10.1002/cam4.1167. Epub 2017 Sep 27.

2.

A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.

Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, Karayan-Tapon L.

BMC Cancer. 2016 Aug 5;16:604. doi: 10.1186/s12885-016-2647-9.

3.

Absence of IDH mutation in colorectal cancers with microsatellite instability.

Tougeron D, Guilloteau K, Karayan-Tapon L.

Dig Liver Dis. 2016 Jun;48(6):681-3. doi: 10.1016/j.dld.2016.02.019. Epub 2016 Mar 2.

PMID:
26987944
4.

Development of pyrosequencing methods for the rapid detection of RAS mutations in clinical samples.

Cortes U, Guilloteau K, Rouvreau M, Archaimbault C, Villalva C, Karayan-Tapon L.

Exp Mol Pathol. 2015 Oct;99(2):207-11. doi: 10.1016/j.yexmp.2015.07.003. Epub 2015 Jul 8.

PMID:
26163758
5.

IL22/IL-22R pathway induces cell survival in human glioblastoma cells.

Akil H, Abbaci A, Lalloué F, Bessette B, Costes LM, Domballe L, Charreau S, Guilloteau K, Karayan-Tapon L, Bernard FX, Morel F, Jauberteau MO, Lecron JC.

PLoS One. 2015 Mar 20;10(3):e0119872. doi: 10.1371/journal.pone.0119872. eCollection 2015.

6.

Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.

Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L.

Mol Cancer Ther. 2014 Sep;13(9):2159-69. doi: 10.1158/1535-7163.MCT-13-1038. Epub 2014 Jul 22.

7.

Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1α, TNFα and oncostatin M.

Rabeony H, Petit-Paris I, Garnier J, Barrault C, Pedretti N, Guilloteau K, Jegou JF, Guillet G, Huguier V, Lecron JC, Bernard FX, Morel F.

PLoS One. 2014 Jul 10;9(7):e101937. doi: 10.1371/journal.pone.0101937. eCollection 2014.

8.

A mesenchymal glioma stem cell profile is related to clinical outcome.

Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J, Bennaceur-Griscelli A, Turhan A, Chomel JC, Karayan-Tapon L.

Oncogenesis. 2014 Mar 17;3:e91. doi: 10.1038/oncsis.2014.5.

9.

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.

Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedeutour F, Karayan-Tapon L.

Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23.

10.

Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1{alpha}, and TNF-{alpha} Recapitulates Some Features of Psoriasis.

Guilloteau K, Paris I, Pedretti N, Boniface K, Juchaux F, Huguier V, Guillet G, Bernard FX, Lecron JC, Morel F.

J Immunol. 2010 May 1;184(9):5263-5270. doi: 10.4049/jimmunol.0902464. Epub 2010 Mar 24.

Supplemental Content

Loading ...
Support Center